Bide Pharmatech Co

Bide Pharmatech Co ROE

The Return on Equity (ROE) of Bide Pharmatech Co (688073.SS) as of Oct 22, 2026 is 7.42 %. In the previous year, Return on Equity (ROE) was 5.79 % — a change of 28.07% (higher).

ROE

7.42 %

YoY

28.07%

Last updated:

In 2025, Bide Pharmatech Co's return on equity (ROE) was 7.42 %, a 28.07% increase from the 5.79 % ROE in the previous year.

The Bide Pharmatech Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2020
16.20 CNY
Jan 1, 2021
15.52 CNY
Jan 1, 2022
7.03 CNY
Jan 1, 2023
5.24 CNY
Jan 1, 2024
5.79 CNY
Jan 1, 2025
7.42 CNY
The Bide Pharmatech Co ROE history
YEARROEYoY
7.42 %+28.07%
5.79 %+10.47%
5.24 %-25.42%
7.03 %-54.69%
15.52 %-4.21%
16.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bide Pharmatech Co Stock analysis

What does Bide Pharmatech Co do? Bide Pharmatech Co., Ltd. generates revenue through the research, development, design, production, and sales of pharmaceutical molecular building blocks and scientific reagents. The company's primary products serve drug target discovery, seed compound screening, lead compound discovery, synthesis, and optimization processes. Key markets include Asia Pacific, India, Europe, and the United States, where the firm's offerings are utilized by pharmaceutical companies and research institutions. The business model relies on direct sales of its specialized chemical products to these industry segments. The firm's main focus is on developing molecular building blocks for drug development, with products specifically designed for early-stage pharmaceutical research. These building blocks are essential for creating and refining potential drug candidates. The company's operations span multiple global regions, targeting pharmaceutical manufacturers and academic research organizations that require high-quality chemical compounds for their development pipelines. Bide Pharmatech's revenue streams are derived from the sale of its proprietary molecular building blocks and reagents, which are integral to pharmaceutical R&D processes. The company serves clients in the pharmaceutical sector across Asia Pacific, India, Europe, and the United States, delivering products that support critical stages of drug discovery and development. Bide Pharmatech Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Bide Pharmatech Co's Return on Equity (ROE)

Bide Pharmatech Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Bide Pharmatech Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Bide Pharmatech Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Bide Pharmatech Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Bide Pharmatech Co stock

Return on Equity (ROE) of Bide Pharmatech Co is 7.42 % in 2025.

Return on Equity (ROE) of Bide Pharmatech Co changed from 5.79 % to 7.42 %, representing a 28.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Bide Pharmatech Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Bide Pharmatech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bide Pharmatech Co

All Key Metrics — Bide Pharmatech Co